9. Clinical benefit table: Euflexxa (Arthrease, BioHy) versus Hylan G‐F 20.
Study | Time | Treatment | Outcome | N of Pts | Baseline Mean | End of Study Mean | Absolute Benefit | Relative Difference |
Thompson 2002 | 1‐4 wk | E: BioHy (Arthrease) | WOMAC pain (0‐100 mm VAS) | 160 | 49.20 | 21.70 | ‐1.00 (I) | ‐1.9% (I) |
C: Hylan G‐F 20 | 161 | 51.90 | 25.40 | |||||
Thompson 2002 | 5‐13 wk | E: BioHy (Arthrease) | WOMAC pain (0‐100 mm VAS) | 160 | 49.20 | 19.20 | ‐1.10 (I) | ‐2.1% (I) |
C: Hylan G‐F 20 | 161 | 51.90 | 23.00 | |||||
Kirchner 2005 | 1‐4 wk | E: Euflexxa | WOMAC physical function (0‐100 mm VAS) | 160 | 47.0 | 22.3 | ‐1.30 (I) | ‐2.6% (I) |
C: Hylan G‐F 20 | 161 | 50.8 | 27.4 | |||||
Kirchner 2005 | 5‐13 wk | E: Euflexxa | WOMAC physical function (0‐100 mm VAS) | 157 | 47.0 | 20.0 | ‐1.60 (I) | ‐3.1% (I) |
C: Hylan G‐F 20 | 158 | 50.8 | 25.4 | |||||
Kirchner 2005 | 1‐4 wk | E: Euflexxa | WOMAC stiffness (0‐100 mm VAS) | 160 | 43.2 | 21.2 | 1.6 (W) | 3.3% (W) |
C: Hylan G‐F 20 | 161 | 47.8 | 24.2 | |||||
Kirchner 2005 | 5‐13 wk | E: Euflexxa | WOMAC stiffness (0‐100 mm VAS) | 157 | 43.2 | 18.2 | 0.8 (W) | 1.7% (W) |
C: Hylan G‐F 20 | 158 | 47.8 | 22.0 |